From Strength to Strength: Unpacking Clinigen's Ro...
Putting patient care at the heart of its mission, Clinigen’s unique approac...
Read MoreThe headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.
Remember:
Get our executive insight into your inbox
Putting patient care at the heart of its mission, Clinigen’s unique approac...
Read MoreAre you considering M&A transactions as a potential exit strategy, step to ...
Read MoreOn the 27th June, we spoke to an expert panel to discuss the how, when, wha...
Read MoreCurrently one of the most successful life science companies in the country,...
Read MoreWe have published our annual investor perception survey, confirming or disp...
Read MoreBiotech and Money recently talked to Simon Newman, CSO of Ryboquin, about t...
Read MoreDaniel Oliver, CEO of Capital Cell, recently took the time to grant us an i...
Read MoreThis is the fourth and final article in our series that aims to provide tip...
Read MoreBiotech and Money recently talked to Mike Westby, CEO of Centauri, about th...
Read MorePhacilitate's Investment for Advanced Therapies in partnership with Biotech...
Read MorePhacilitate's Investment for Advanced Therapies in partnership with Biotech...
Read MoreHighlights Capital Cell’s crowdfunding campaign - Bionure - overfunds with ...
Read MoreThe Drugs & Dealers Blog provides genuine thought leadership, exclusive executive insight and market intelligence on the life science and healthcare investment sector.
In partnership with Medius Associates
Medius' monthly review of the top deals by value in the healthcare sector
Connecting Europe's Life Science corporates with capital.
Biotech and Money is the influential community of senior life science decision makers
© 2016 All Rights Reserved By Biotech and Money
Add Your Response